Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 32
Filtrar
1.
Euro Surveill ; 26(4)2021 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-33509337

RESUMO

Healthcare workers (HCWs) are at increased risk of both exposure and transmission of infectious disease. Two European Union (EU) directives state that health services are responsible for assessing their employees' potential exposure to infectious diseases and offering immunisation free of charge. We assessed current policy for immunisation of HCWs and the availability of vaccine coverage data in the Nordic countries by surveying national vaccination experts in Denmark, Finland, Iceland, Norway and Sweden, as well as Swedish county medical officers (CMOs). All national experts and 17 of 21 Swedish CMOs responded. All EU countries had transposed the European directives into national law, while Norway and Iceland had similar national legislation. Recommendations or guidelines were issued in Denmark, Finland, Iceland, Norway and 15 of 17 responding Swedish counties. The range of diseases covered differed by countries and Swedish counties. HCW vaccine coverage data were not systematically collected; incomplete estimates were only available for Finland and two Swedish counties. In conclusion, recommendations or guidelines exist in the Nordic countries, but their impact cannot be assessed, as vaccine uptake among HCWs is not currently measured. Systematic collection of data is a necessary step towards improving HCW immunisation policy and practice in the Nordic countries.


Assuntos
Pessoal de Saúde , Vacinação , Finlândia , Humanos , Islândia/epidemiologia , Noruega/epidemiologia , Países Escandinavos e Nórdicos/epidemiologia , Suécia/epidemiologia
4.
Hum Vaccin Immunother ; 14(10): 2472-2477, 2018.
Artigo em Inglês | MEDLINE | ID: mdl-29771601

RESUMO

Limited data exist on the immunogenicity of a third dose of the measles, mumps, and rubella vaccine (MMR). In this study, our aim was to evaluate the long-term rubella immunogenicity afforded by two childhood MMR doses of the Norwegian vaccination program in a cohort of conscripts and to determine the effect of an additional dose of MMR vaccine, in order to inform vaccination policy. Blood samples from Norwegian conscripts (n = 495) taken both before and eight months after administration of a dose of MMR vaccine were tested using an enzyme immunoassay to measure anti-rubella IgG. Concentrations <5 IU/mL were regarded as negative, 5.0-9.9 IU/mL as equivocal, and ≥10 IU/mL as positive. Overall, the seropositivity before vaccination was 84.6%, and 99.0% of the conscripts had anti-rubella IgG concentrations ≥5 IU/mL. The seropositivity after vaccination was 94.5%, and 99.8% of the conscripts had antibody concentrations ≥5 IU/mL. The geometrical mean IgG concentrations increased from 21.4 IU/mL before vaccination to 28.9 IU/mL after. Four out of five conscripts, with seronegative concentrations before administrations of an additional MMR dose, had equivocal or seropositive results following vaccination. The cohort of young adults in Norway, which was eligible for two childhood MMR doses, was protected against rubella, and efforts should be made to maintain high vaccine coverage to ensure immunity in the future. A third dose of MMR administered in early adulthood led to an increase in the antibody concentration in our cohort and seroconversion for the majority of seronegative persons.


Assuntos
Anticorpos Antivirais/sangue , Imunização Secundária/métodos , Vacina contra Sarampo-Caxumba-Rubéola/administração & dosagem , Vacina contra Sarampo-Caxumba-Rubéola/imunologia , Rubéola (Sarampo Alemão)/prevenção & controle , Adolescente , Adulto , Criança , Estudos de Coortes , Ensaio de Imunoadsorção Enzimática , Feminino , Humanos , Esquemas de Imunização , Imunoglobulina G/sangue , Masculino , Noruega , Adulto Jovem
5.
Vaccine ; 34(17): 2015-20, 2016 Apr 12.
Artigo em Inglês | MEDLINE | ID: mdl-26947498

RESUMO

BACKGROUND: Selective immunisation is an alternative to universal vaccination if children at increased risk of disease can be identified. Within the Norwegian Childhood Immunisation Programme, BCG vaccine against tuberculosis and vaccine against hepatitis B virus (HBV) are offered only to children with parents from countries with high burden of the respective disease. We wanted to study whether this selective immunisation policy reaches the targeted groups. METHODS: The study population was identified through the Norwegian Central Population Registry and consisted of all children born in Norway 2007-2010 and residing in Norway until their second birthday, in total 240,484 children. Information on vaccinations from the Norwegian Immunisation Registry, and on parental country of birth from Statistics Norway, was linked to the population registry by personal identifiers. The coverage of BCG and HBV vaccine was compared with the coverage of vaccines in the universal programme. RESULTS: Among the study population, 16.1% and 15.9% belonged to the target groups for BCG and HBV vaccine, respectively. Among children in the BCG target group the BCG vaccine coverage was lower than the coverage of pertussis and measles vaccine (83.6% vs. 98.6% and 92.3%, respectively). Likewise, the HBV vaccine coverage was lower than the coverage of pertussis and measles vaccine in the HBV target group (90.0% vs. 98.6% and 92.3%, respectively). The coverage of the targeted vaccines was highest among children with parents from South Asia and Sub-Saharan Africa. The coverage of vaccines in the universal programme was similar in targeted and non-targeted groups. CONCLUSIONS: Children targeted by selective vaccination had lower coverage of the target vaccines than of vaccines in the universal programme, indicating that selective vaccination is challenging. Improved routines for identifying eligible children and delivering the target vaccines are needed. Universal vaccination of all children with these vaccines could be considered.


Assuntos
Vacina BCG/uso terapêutico , Vacinas contra Hepatite B/uso terapêutico , Hepatite B/prevenção & controle , Tuberculose/prevenção & controle , África Subsaariana/etnologia , Ásia/etnologia , Criança , Necessidades e Demandas de Serviços de Saúde , Humanos , Programas de Imunização , Noruega/epidemiologia , Sistema de Registros , Vacinação/estatística & dados numéricos
6.
BMC Pediatr ; 15: 180, 2015 Nov 13.
Artigo em Inglês | MEDLINE | ID: mdl-26563381

RESUMO

BACKGROUND: Delayed vaccinations increase the risk for vaccine preventable diseases (VPDs). Monitoring of delayed vaccinations by using a national immunisation registry has not been studied in countries recommending a two-dose (3 and 5 months of age) primary series of e.g., pertussis vaccine. Surveillance/monitoring of all vaccinations may improve vaccination programmes functioning. METHODS: We obtained information from the Norwegian immunisation registry (SYSVAK) on all programme vaccinations received at age up to 730 days in children born in 2010 (n = 63,382). Timely vaccinations were received up to 7 days after the recommended age. Vaccinations were considered delayed if they were received more than one month after the recommended age in the schedule. RESULTS: In vaccinated children, timely administration of the subsequent three doses of pertussis and one dose of measles occurred in 73.8, 47.6, 53.6 and 43.5 % respectively. Delay for one or more programme vaccinations (diphtheria, tetanus, pertussis, polio, Haemophilus influenza type B, invasive pneumococcal disease, measles, mumps or rubella) was present in 28,336 (44.7 %) children. Among those who were delayed the mean duration was 139 days. The proportion of children that had vaccinations delayed differed among counties (range 37.4 %-57.8 %). Immigrant children were more frequently delayed 52.3 % vs. 43.1 %, RR 1.21 (95 % CI 1.19, 1.24). Children scheduled for vaccines in the summer holiday month (July) were more frequently delayed than others (1(st) dose pertussis vaccine 6.5 % vs. 3.9 % RR 1.65 (95 % CI 1.48, 1.85). Priming against pertussis (2(nd) dose), pneumococcal (2(nd) dose) and measles (1(st) dose) was delayed in 16.8, 18.6 and 29.3 % respectively. CONCLUSION: Vaccinations were frequently delayed. Delayed vaccinations differed among counties and occurred more frequently during the summer vacation (July) and in the immigrant population. Monitoring improves programme surveillance and may be used on an annual basis.


Assuntos
Esquemas de Imunização , Vacinação , Pré-Escolar , Emigrantes e Imigrantes , Humanos , Lactente , Noruega , Sistema de Registros , Fatores de Tempo
8.
J Med Virol ; 86(5): 820-6, 2014 May.
Artigo em Inglês | MEDLINE | ID: mdl-24114849

RESUMO

Infections caused by cytomegalovirus (CMV), parvovirus B19 (B19), and rubella can lead to serious complications in pregnant women. The aim of this study was to determine the susceptibility to CMV, B19, and rubella antibodies in pregnant women in Norway. Consecutive sera samples were collected from pregnant women in two different regions in Norway. Sera were collected from age groups; ≤19, 20-24, 25-29, 30-34, 35-39, and ≥40 years old. Of the 2,000 pregnant women tested, anti-CMV IgG was positive in 62.8% anti-parvovirus B19 IgG in 59.7% and anti-rubella IgG in 94.4%. CMV IgG susceptibility has decreased in pregnant women less than 30 years of age, from 60% in a study conducted in 1973-1974 to 37.2% in present study. There was a significant difference in CMV IgG seropositivity rate between the two regions (58.6% and 67.1%). Serum levels of rubella IgG was lowest in age group 25-29 years with a positivity rate of 91.0%. Women born before vaccination with two doses of MMR started, had both a higher positivity rate and significantly higher levels of rubella antibody titre, 96.1% and 82.2 IU/ml compared to those born after 92.9% and 41.7 IU/ml. Significantly lower anti-rubella IgG titre found in the youngest age groups highlights the need for continued antenatal screening. A considerable increase in anti-CMV-IgG seropositivity rate was observed and might be associated with higher rate of breastfeeding and a higher percentage attending day-care centres.


Assuntos
Anticorpos Antivirais/sangue , Infecções por Citomegalovirus/imunologia , Suscetibilidade a Doenças , Infecções por Parvoviridae/imunologia , Rubéola (Sarampo Alemão)/imunologia , Adolescente , Adulto , Fatores Etários , Feminino , Humanos , Imunoglobulina G/sangue , Noruega , Gravidez , Gestantes , Adulto Jovem
9.
N Engl J Med ; 368(4): 333-40, 2013 Jan 24.
Artigo em Inglês | MEDLINE | ID: mdl-23323868

RESUMO

BACKGROUND: During the 2009 influenza A (H1N1) pandemic, pregnant women were at risk for severe influenza illness. This concern was complicated by questions about vaccine safety in pregnant women that were raised by anecdotal reports of fetal deaths after vaccination. METHODS: We explored the safety of influenza vaccination of pregnant women by linking Norwegian national registries and medical consultation data to determine influenza diagnosis, vaccination status, birth outcomes, and background information for pregnant women before, during, and after the pandemic. We used Cox regression models to estimate hazard ratios for fetal death, with the gestational day as the time metric and vaccination and pandemic exposure as time-dependent exposure variables. RESULTS: There were 117,347 eligible pregnancies in Norway from 2009 through 2010. Fetal mortality was 4.9 deaths per 1000 births. During the pandemic, 54% of pregnant women in their second or third trimester were vaccinated. Vaccination during pregnancy substantially reduced the risk of an influenza diagnosis (adjusted hazard ratio, 0.30; 95% confidence interval [CI], 0.25 to 0.34). Among pregnant women with a clinical diagnosis of influenza, the risk of fetal death was increased (adjusted hazard ratio, 1.91; 95% CI, 1.07 to 3.41). The risk of fetal death was reduced with vaccination during pregnancy, although this reduction was not significant (adjusted hazard ratio, 0.88; 95% CI, 0.66 to 1.17). CONCLUSIONS: Pandemic influenza virus infection in pregnancy was associated with an increased risk of fetal death. Vaccination during pregnancy reduced the risk of an influenza diagnosis. Vaccination itself was not associated with increased fetal mortality and may have reduced the risk of influenza-related fetal death during the pandemic. (Funded by the Norwegian Institute of Public Health.).


Assuntos
Morte Fetal/prevenção & controle , Vírus da Influenza A Subtipo H1N1 , Vacinas contra Influenza , Influenza Humana/complicações , Complicações Infecciosas na Gravidez , Adolescente , Adulto , Feminino , Morte Fetal/etiologia , Humanos , Vacinas contra Influenza/efeitos adversos , Influenza Humana/epidemiologia , Influenza Humana/prevenção & controle , Pessoa de Meia-Idade , Noruega/epidemiologia , Pandemias , Gravidez , Complicações Infecciosas na Gravidez/prevenção & controle , Modelos de Riscos Proporcionais , Risco , Adulto Jovem
10.
Vaccine ; 30 Suppl 2: B57-62, 2012 May 30.
Artigo em Inglês | MEDLINE | ID: mdl-22607900

RESUMO

The development of conjugate vaccines has enabled the prevention and control of Neisseria meningitidis caused by serogroups A, C, W-135 and Y. Vaccines that provide protection against a broad number of serogroup B strains likely will be available soon to enable greater control of meningococcal disease in high income countries. We present an argument for adequate post-marketing surveillance to monitor epidemiological shifts and to provide a context for the safety and reactogenicity of serogroup B vaccines, including the newer recombinant vaccines. We also offer a series of recommendations to address possible concerns about vaccine safety.


Assuntos
Infecções Meningocócicas/epidemiologia , Infecções Meningocócicas/prevenção & controle , Vacinas Meningocócicas/administração & dosagem , Vacinas Meningocócicas/imunologia , Neisseria meningitidis/isolamento & purificação , Vigilância de Evento Sentinela , Países Desenvolvidos , Humanos , Meningites Bacterianas/epidemiologia , Meningites Bacterianas/prevenção & controle , Neisseria meningitidis/classificação , Neisseria meningitidis/imunologia , Vigilância de Produtos Comercializados/métodos , Sepse/epidemiologia , Sepse/prevenção & controle
13.
Vaccine ; 27(1): 23-7, 2009 Jan 01.
Artigo em Inglês | MEDLINE | ID: mdl-18984023

RESUMO

The etiology of chronic fatigue syndrome (CFS)/myalgic encephalomyelitis (ME) is unknown. In Norway, a vaccine against Neisseria meningitides group B was administered to teenagers in 1988--1989 in a protection trial. In order to estimate the relative risk of CFS/ME according to vaccine history, we conducted a case-control study in 2007, with 201 cases diagnosed at one of two hospitals and 389 controls. The adjusted odds ratio for CFS/ME was 1.06 (95% CI: 0.67-1.66) for subjects who received the active vaccine contrasted to subjects who did not. Using this design, no statistically significant association between vaccination against meningococcal disease in teenagers and occurrence of CFS/ME could be observed.


Assuntos
Síndrome de Fadiga Crônica/epidemiologia , Infecções Meningocócicas/prevenção & controle , Vacinas Meningocócicas/administração & dosagem , Vacinas Meningocócicas/efeitos adversos , Adulto , Estudos de Casos e Controles , Estudos de Coortes , Síndrome de Fadiga Crônica/etiologia , Feminino , Humanos , Programas de Imunização , Masculino , Infecções Meningocócicas/epidemiologia , Fatores de Risco , Vacinação/efeitos adversos , Adulto Jovem
14.
Expert Rev Vaccines ; 6(5): 863-9, 2007 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-17931164

RESUMO

Throughout the history of vaccination, vaccines have been accused of harmful side effects. Adverse events following immunization may be caused by the active antigen in the vaccine or other constituents, such as adjuvants, or may merely be coincidental. Possible neurological side effects have always obtained high attention. However, the risk of serious events caused by existing vaccines or aluminum adjuvants is very small. Currently, there are several new vaccines and adjuvants in the pipeline. Of these vaccines, many will be offered mainly to adolescents or adults. When taken into general use, some of them will probably be associated with serious adverse events. Although coincidence will be the most probable explanation in most cases, causality will have to be discussed in many situations. Preparing to address the causes of these adverse events is important.


Assuntos
Adjuvantes Imunológicos/efeitos adversos , Compostos de Alumínio/efeitos adversos , Proteínas da Membrana Bacteriana Externa/efeitos adversos , Vacinas Meningocócicas/efeitos adversos , Neisseria meningitidis Sorogrupo B/imunologia , Doenças do Sistema Nervoso/induzido quimicamente , Animais , Humanos , Infecções Meningocócicas/prevenção & controle , Doenças do Sistema Nervoso/diagnóstico , Doenças do Sistema Nervoso/epidemiologia
15.
Clin Vaccine Immunol ; 14(9): 1062-9, 2007 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-17634513

RESUMO

MenBvac and MeNZB are safe and efficacious vaccines against serogroup B meningococcal disease. MenBvac is prepared from a B:15:P1.7,16 meningococcal strain (strain 44/76), and MeNZB is prepared from a B:4:P1.7-2,4 strain (strain NZ98/254). At 6-week intervals, healthy adults received three doses of MenBvac (25 microg), MeNZB (25 microg), or the MenBvac and MeNZB (doses of 12.5 microg of each vaccine) vaccines combined, followed by a booster 1 year later. Two-thirds of the subjects who received a monovalent vaccine in the primary schedule received the other monovalent vaccine as a booster dose. The immune responses to the combined vaccine were of the same magnitude as the homologous responses to each individual vaccine observed. At 6 weeks after the third dose, 77% and 87% of the subjects in the combined vaccine group achieved serum bactericidal titers of > or = 4 against strains 44/76 and NZ98/254, respectively, and 97% and 93% of the subjects achieved a fourfold or greater increase in opsonophagocytic activity against strains 44/76 and NZ98/254, respectively. For both strains, a trend of higher responses after the booster dose was observed in all groups receiving at least one dose of the respective strain-specific vaccine. Local and systemic reactions were common in all vaccine groups. Most reactions were mild or moderate in intensity, and there were no vaccine-related serious adverse events. The safety profile of the combined vaccine was not different from those of the separate monovalent vaccines. In conclusion, use of either of the single vaccines or the combination of MenBvac and MeNZB may have a considerable impact on the serogroup B meningococcal disease situation in many countries.


Assuntos
Proteínas da Membrana Bacteriana Externa/imunologia , Infecções Meningocócicas/prevenção & controle , Vacinas Meningocócicas/administração & dosagem , Neisseria meningitidis Sorogrupo B/imunologia , Adulto , Ensaio de Imunoadsorção Enzimática , Feminino , Humanos , Esquemas de Imunização , Imunização Secundária , Imunoglobulina G/sangue , Masculino , Infecções Meningocócicas/imunologia , Infecções Meningocócicas/microbiologia , Vacinas Meningocócicas/efeitos adversos , Vacinas Meningocócicas/imunologia , Fagocitose/imunologia , Polissacarídeos Bacterianos/administração & dosagem , Polissacarídeos Bacterianos/imunologia , Vacinas Combinadas/administração & dosagem , Vacinas Combinadas/efeitos adversos , Vacinas Combinadas/imunologia
19.
Tidsskr Nor Laegeforen ; 126(19): 2538-40, 2006 Oct 05.
Artigo em Norueguês | MEDLINE | ID: mdl-17028636

RESUMO

Development of vaccines has in many ways been the art of the possible, using current knowledge about infections and microbes to devise new products. The aim of every vaccination is to prevent disease, but use of vaccines within vaccination programs is usually targeted not only to protect the individual, but also to changing the epidemiology of the disease. Several new vaccines will become available during the next decade, but the vaccination program will probably not be dramatically changed. Increased knowledge about the immune system might, in a longer time perspective, make it possible to rebuild a vaccination program on a new basis. Immunisations can perhaps be used for targeting the immune system in ways that still give protection against the specific infections, but in addition lead to better health through general protection against diseases, less allergy and less autoimmune diseases than we have today.


Assuntos
Programas de Imunização/história , Vacinação , Vacinas Bacterianas/história , História do Século XIX , História do Século XX , Humanos , Programas de Imunização/tendências , Noruega , Vacinação/história , Vacinação/tendências , Vacinas Virais/história
20.
Tidsskr Nor Laegeforen ; 126(19): 2541-4, 2006 Oct 05.
Artigo em Norueguês | MEDLINE | ID: mdl-17028637

RESUMO

When the diseases we try to prevent through vaccination are rare, we tend to focus more on the associated risks. Vaccination has led to unfortunate consequences, mainly due to production failure and inadequate control in earlier years. The requirements for vaccine control are now so rigorous that the risk for such occurrences is close to zero. Local and mild systemic reactions to vaccines are rather common, and are usually well known and described in detail when a vaccine is licensed. Some vaccine reactions are however so rare that they only will be discovered through surveillance after the vaccine has become available for routine use. Suspicion of adverse events will now normally arise through the official notification systems for adverse events. Large epidemiological studies are often necessary to decide whether there is a causal relationship or only a coincidence. Recording of adverse events following vaccination and transparency about their existence, are important issues in the work to maintain the credibility of vaccines.


Assuntos
Vacinas Bacterianas/efeitos adversos , Vacinação/efeitos adversos , Vacinas Virais/efeitos adversos , Sistemas de Notificação de Reações Adversas a Medicamentos , Criança , Humanos , Programas de Imunização , Noruega , Sistema de Registros , Fatores de Risco , Estados Unidos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...